SCHEMBL2118508

SCHEMBL2118508

O=C1C(Cc2ccccc2Cl)N=C(Cl)c2cc(Cl)ccc2N1C1CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRK1 P41145 2/20 0.38
CHRM2 P08172 1/20 0.38
ADRA2A P08913 1/20 0.38
PDE4D Q08499 1/20 0.38
CES2 O00748 2/20 0.36
OPRM1 P35372 2/20 0.35
CMA1 P23946 1/20 0.35
LMNA P02545 2/20 0.35
P2RX7 Q99572 2/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
HTT P42858 1/20 0.35
PDE3A Q14432 1/20 0.34
TP53 P04637 2/20 0.33
CHRM1 P11229 1/20 0.33
GABRP O00591 1/20 0.33
GABRD O14764 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRB1 P18505 1/20 0.33
GABRG2 P18507 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1515145 0.83 OPRK1 (0.53) OPRK1CHRM2ADRA2APDE4DCES2
SCHEMBL2117702 0.81 OPRK1 (0.36) OPRK1CHRM2ADRA2APDE4DLMNA
SCHEMBL1515156 0.80 OPRK1 (0.40) OPRK1CHRM2ADRA2APDE4DCES2
SCHEMBL2120238 0.78 ROCK2 (0.43) OPRM1CMA1LMNAP2RX7ALDH1A1
SCHEMBL12099078 0.75 TSHR (0.43) OPRK1CHRM2ADRA2APDE4DCMA1
SCHEMBL1515025 0.75 TSHR (0.43) OPRK1CHRM2ADRA2APDE4DCMA1
SCHEMBL1514972 0.75 TSHR (0.43) OPRK1CHRM2ADRA2APDE4DCMA1
SCHEMBL14707966 0.72 OPRK1 (0.47) OPRK1CHRM2ADRA2APDE4DLMNA
SCHEMBL1515184 0.72 OPRK1 (0.47) OPRK1CHRM2ADRA2APDE4DLMNA
SCHEMBL2121623 0.72 OPRK1 (0.54) OPRK1CHRM2ADRA2APDE4DLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8604023-B2 1,4-benzodiazepinone compounds and their use in treating cancer THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2013-12-10 US disclosed
US-20120094982-A1 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2012-04-19 US disclosed
US-20120094982-A1 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2012-04-19 US disclosed
US-20120094982-A1 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2012-04-19 US disclosed
WO-2010121164-A2 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2010-10-21 WO disclosed
WO-2010121164-A2 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2010-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094982-A1 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER HTR4, HTR1A, HTR3B OPRK1 21/4885CHRM2 971/4885ADRA2A 187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.